Objectives Chronic use of benzodiazepines and z-drugs (BZD/Zs), the most commonly used symptomatic treatment for sleep problems, is discouraged because of the unproven long-term effectiveness. In this study, we evaluated 1-year evolution of subjective sleep quality of chronic BZD/Z users compared with nonusers. Methods All cognitively competent residents from ten Belgian nursing homes were screened and compiled in a group of chronic BZD/Z users or nonusers, based on the medication chart. We collected demographic, functional and psychometric characteristics (depressive symptoms with the 8-item Geriatric Depression Scale), sleep parameters (with the Pittsburgh Sleep Quality Index-PSQI) and medication use. We analysed evolution of sleep quality with nonparametric statistics. Associations with worsening of sleep quality were analysed with linear regression. Results We collected data of 131 BZD/Z users and 95 nonusers. The mean age in both groups was 85 years and 77 % was female. Over a period of 1 year, the PSQI score evolved from 5.2 to 5.8 (p = 0.035) in the BZD/Z users, and from 4.3 to 4.7 (p = 0.078) in the nonusers. Though the mean deterioration in 1 year did not differ significantly between both groups, the BZD/Z users had a significantly worse sleep quality compared with nonusers at both time points. Depressive symptoms were significantly associated with worsening sleep quality (b = -0.243, p \ 0.001). Conclusion Sleep quality in chronic BZD/Z users significantly decreased over 1 year and was significantly worse than in nonusers at the end of this period. This study suggests that using BZD/Zs chronically does not maintain or improve sleep quality. Depressive symptoms are an important factor in the deterioration of sleep quality.
Introduction
Benzodiazepines and related z-drugs (BZD/Zs) are the most frequently used symptomatic treatment for sleep problems in the older population and particularly in the nursing-home setting [1, 2] . Although BZD/Zs alter the sleep architecture by suppressing deep sleep stages, they are initiated because they shorten the time to fall asleep and increase total sleep duration [3] . Due to their sedating action, the (short-term) adverse effects of BZD/Zs include decreased alertness with risk of falls [4] and anterograde amnesia. Although most patients engage in chronic use, the hypnotic effect decreases due to tolerance [5] . Due to the risk of adverse drug events and drug dependence, guidelines advise short-term use of BZD/Zs. Interruption of treatment can lead to withdrawal symptoms [6] , and this is often the reason for continued use.
Long-term effectiveness is difficult to assess and requires long-term follow-up data. Until now, there have been no randomised controlled studies published that have investigated the long-term effectiveness of chronic BZD/Z use (maximum follow-up time is 6 months [7] ). Epidemiological studies of the effects of chronic BZD/Z use on sleep quality [8] [9] [10] [11] indicate worse sleep quality. But longitudinal studies that investigate the temporal evolution of sleep quality are scarce [12] , especially in older people residing in nursing homes [13] . Moreover, most studies on BZDs do not differentiate between the indication insomnia or anxiety.
Our aim was to investigate the 1-year evolution of sleep quality in a well defined group of chronic BZD/Z users (indicated for insomnia) and compare this with a well defined group of nonusers. Furthermore, we investigated which demographic, functional, psychometric and clinical characteristics and medications were associated with worsening sleep quality over time.
Methods
In this longitudinal cohort study in the Belgian nursing home setting, we compared the 1-year evolution of sleep quality in chronic BZD/Z users with nonusers, all cognitively competent. The methodology and baseline findings have been previously published elsewhere [11] .
Design
From a convenience sample of ten nursing homes, all residents who were cognitively competent to respond to questionnaires (defined as having a Mini Mental State Examination [MMSE] [14] score of at least 18 out of 30 [15] ) were identified. We excluded residents who only used the antidepressants trazodone or mirtazapine or phytotherapy as a sleep medication, and residents that used BZDs for the indication anxiety (defined as daytime use of BZDs). Residents with BZDs or z-drugs administered at bedtime for at least 3 months were allocated to the BZD/Z group. Residents free of any hypnotic medication were allocated to the nonuser group. Both groups were evaluated at baseline (December 2011-January 2012) and after 1 year (January 2013).
Data Collection
Demographic data were obtained from the resident's record and medication data from the medication chart. Clinical data included mental competence (assessed with MMSE), hearing and visual problems, and functionality (Activities of Daily Living [ADL]).
Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI) [16] , a self-rated questionnaire for global sleep quality and specific aspects of sleep disturbance. The seven components of the PSQI are each scored from 0 to 3 with higher scores indicating worse sleep quality. Similar to other studies [10, 17] , we used an adjusted PSQI score that can range from 0 to 19. This adjusted score excludes the PSQI component 'sleep medication' because of its full correlation with BZD/Z use. The widely used cut-off of 5 was used to indicate poor sleep quality.
At 1-year follow-up, additional items were investigated. Depressive symptoms were scored with the 8-item Geriatric Depression Scale (GDS-8) [18] . This abbreviated version of the GDS-30 was designed and validated for nursing-home residents. A score of 3 or more on the GDS-8 indicates depression. Additionally, we recorded number of falls by checking the medical file. We also recorded the presence of restless legs, frequent pain, frequency of social activities, social contacts (visitors in and out of the nursing home) and mental stimuli (watching TV, reading, memory games).
Ethical Considerations
This observational cohort study was approved by the ethics committee of the University Hospital of Antwerp (registration number B300201112211). Each nursing home received information and approved the screening of residents. Each resident included in our study received oral and written information, and gave their consent.
Statistics
The analysis and presentation of our results focused on the residents still included at 1-year follow-up was based on initial group assignment.
Demographic, functional, psychometric and medication characteristics were described and compared between the BZD/Z group and the control group, using percentages and Chi 2 for categorical variables and means and independent t tests for continuous variables. Nonparametric statistics were used with scaling results.
Sleep evolution was presented with mean adjusted PSQI scores and standard deviations (SD) and analysed with a Wilcoxon Signed Rank test. Differences in adjusted PSQI scores between both groups were analysed with a Mann Whitney U test.
Multiple linear regression was used to analyse the associations between demographic, functional, and clinical characteristics, and medication and worsening sleep quality (difference in adjusted PSQI score between the baseline and the 12-month assessment).
Results
At baseline, 300 residents met the inclusion criteria: 178 BZD/Z users and 122 nonusers (sleep characteristics are previously published [11] . After 1 year, we had follow-up data of 226 residents; 131 BZD/Z users and 95 nonusers.
There were no differences in characteristics between residents lost to follow-up (n = 74) and residents still in the study (n = 226) at 1 year, except for the baseline MMSE score, which was 1 point lower in the residents lost to follow-up (25.8 vs 24.9, p = 0.015). Mortality was an important cause of lost to follow-up in both groups (16.3 % in the BZD/Z group and 11.5 % in the control group, p = 0.253).
Comparison of Benzodiazepine/Z-Drug (BZD/Z)
Users' Characteristics with Nonusers at 1 Year
The comparison of BZD/Z users' clinical, psychometric characteristics and medication information with that of nonusers is presented in Table 1 . The demographic and clinical profile of the BZD/Z users and the nonusers was similar except for depressive symptoms, which were more frequent among the BZD/Z users (43 vs 27 %). The BZD/Z users played fewer memory games compared with the control group (31 vs 45 %). The BZD/Z group took significantly more chronic medications compared with the control group (mean 9.1 vs 7.5), with a larger intake of pain medications.
The most frequently used BZD/Zs at baseline (n = 131) were lormetazepam (34 %), zolpidem (26 %) and lorazepam (23 %). Short-/intermediate-acting BZD/Z were used in 90 % (n = 118) and long-acting in 14 % (n = 18) of the users (4 % of users used both).
Sleep Evolution in the BZD/Z Users Compared with Nonusers
Over a period of 1 year, in the BZD/Z group, the adjusted PSQI score evolved from 5.2 (SD 2.4) to 5.8 (SD 3.1) (p = 0.035) and in the nonusers from 4.3 (SD 2.3) to 4.7 (SD 2.9) (p = 0.078). The mean deterioration in both groups did not differ significantly (Fig. 1) .
The percentage of bad sleepers (adjusted PSQI [5) was larger in the BZD/Z group compared with the nonusers at baseline (39.7 vs 28.4 % p = 0.079) and increased in 1 year (45.8 vs 27.7 % p = 0.006). In the BZD/Z group, 19.5 % became bad sleepers compared with 11.7 % of nonusers (NS).
Associations with Sleep Quality Worsening
In the univariate analysis, we did not find a correlation between worsening sleep quality and any demographic (age, gender, educational level), medication, or functional or clinical characteristic except for depressive symptoms (b = -0.235, p \ 0.001) ( Table 2 ). In multivariate analysis controlled for age, gender and BZD/Z use, depressive symptoms were significantly associated with worsening sleep quality (b = -0.243, p \ 0.001) ( Table 2 ).
Discussion
During the 1-year follow-up period, the sleep quality of the BZD/Z users deteriorated significantly, while in the nonusers there was also a deterioration in sleep quality, although not significant. The rate at which this deterioration occurred did not differ significantly between BZD/Z users and nonusers, though the sleep quality in chronic BZD/Z users was significantly worse compared with nonusers both at baseline and at 1-year follow-up.
In both groups, the sleep quality deteriorated, which can be partly explained by aging [19] or comorbidities [20] . The comorbidity 'depression' was, in this study, a significant factor in worsening sleep quality. Depression and sleep problems are often linked together [21, 22] (e.g., sleep problems are often included in depressive symptoms). In this study, depressive symptoms were also more prevalent in chronic BZD/Z users compared with nonusers. There is a complex relationship between sleep and depression that needs further investigation. Moreover, residents with BZD/Zs take more chronic medication, especially psychotropic medication. Polypharmacy and psychotropic drugs could influence sleep quality and its evolution. Although we did not find explicit factors besides depression related to worsening sleep quality, other influences such as pain and other comorbidities cannot be ruled out.
Our study shows that chronic use of BZD/Z does not maintain or improve sleep quality. We now know that the sleep quality of chronic BZD/Z users is worse than in nonusers and it does not improve (over 1 year). A study in community-dwelling older adults also found a worse sleep quality in long-term BZD/Z users [10] and reported a negative impact on evolution compared with nonusers [12] .
This was the first study especially designed to investigate sleep quality and its temporal evolution among a well defined group of chronic BZD/Z users in the nursing-home setting and compare it with a well defined control group (free of any hypnotic) using an adequate tool that reports several aspects of sleep quality. In order to reduce indication bias, we included residents who used BZD/Zs only at bedtime as a proxy for the indication insomnia. Nevertheless, indication bias cannot be completely ruled out because we did not ask the GP for confirmation of this indication. Another strength was the inclusion of several risk factors such as functionality, social status, depressive symptoms and medication use. Several limitations are inherent to the study design. We used a convenience rather than a representative sample of nursing homes. However, the respondents' characteristics were comparable to the general Belgian nursing-home population (age, gender, chronic drug intake) [23] . Although there were no noticeable differences between residents lost to follow-up and residents in the study, selection bias cannot be excluded. Unfortunately, we had no information about specific sleep disorders, specific medications other than psychotropics or narcotics that could influence sleep quality, or past BZD/Z use and duration of use. However, in most residents, BZD/ Z is already present at nursing-home admission and remains on the medication list for a long period of time [24] [25] [26] . Although the study adds to the knowledge that chronic continuation is not recommended in terms of sleep quality, we did not investigate incident users and baseline sleep parameters. Longitudinal studies with incident BZD/ Z users followed over a longer period of time (i.e., more than 6 months) are lacking. In future research, it is recommended to monitor the evolution of sleep quality in incident users and to investigate the consequences of BZD/ Z discontinuation on sleep. 
Conclusion
Sleep quality in chronic BZD/Z users significantly decreased over 1 year and was significantly worse than in nonusers 1 year later. This study suggests that using BZD/ Zs chronically does not maintain or improve sleep quality. Depressive symptoms are an important factor in the deterioration of sleep quality.
